

References

S-241

1. Panchal P, Budree S, Scheeler A, et al. Scaling safe access to fecal microbiota transplantation: Past, present, and future. *Curr Gastroenterol Rep.* 2018;20(4):14.
2. Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial. 2019;321(2):156-164.
3. US Food and Drug Administration. Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms 2019.
4. McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis.* 2018;66(7).
5. Hayes, Inc. Emerging Technology Report. *SER-109 for Fecal Microbiota Transplantation.* Lansdale, PA: Hayes, Inc.; 08/26/2022.
6. Hayes, Inc. Emerging Technology Report. *RBX2660 for Fecal Microbiota Transplantation.* Lansdale, PA: Hayes, Inc.; 09/26/2022.
7. Jiang ZD, Jenq RR, Ajami NJ, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent *Clostridium difficile* infection: A randomized clinical trial. *PLoS One.* 2018;13(11):e0205064.
8. US Food and Drug Administration. Fecal microbiota for transplantation: New safety information – Regarding additional protections for screening donors for COVID-19 and exposure to SARS-CoV-2 and testing for SARS-CoV-2. 2020.
9. Tariq R, Pardi DS, Bartlett MG, Khanna S. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent *Clostridium difficile* infection: A systematic review and meta-analysis. *Clin Infect Dis.* 2019;68(8):1351-1358.
10. Rokkas T, Gisbert JP, Gasbarrini A, et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota

transplantation in recurrent *Clostridium difficile* infection. *United European Gastroenterol J*. 2019;7(8):1051-1063.

11. Khan MY, Dirweesh A, Khurshid T, Siddiqui WJ. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent *Clostridium difficile* infection: A systematic review and meta-analysis. *Eur J Gastroenterol Hepatol*. 2018;30(11):1309-1317.
12. Mamo Y, Woodworth MH, Wang T, Dhere T, Kraft CS. Durability and long-term clinical outcomes of fecal microbiota transplant treatment in patients with recurrent *Clostridium difficile* Infection. *Clin Infect Dis*. 2018;66(11):1705-1711.
13. Crothers JW, Chu ND, Nguyen LTT, et al. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. *BMC Gastroenterol*. 2021;21(1):281.
14. Fang H, Fu L, Li X, et al. Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: A prospective randomized pilot study. *Microb Cell Fact*. 2021;20(1):18.
15. Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: Efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther*. 2019;50(3):240-248.
16. Saha S, Tariq R, Tosh PK, Pardi DS, Khanna S. Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: A systematic review. *Clin Microbiol Infect*. 2019;25(8):958-963.
17. Proença IM, Allegretti JR, Bernardo WM, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: Systematic review with meta-analysis based on randomized clinical trials. *Nutr Res*. 2020;83:1-14.
18. Cold F, Kousgaard SJ, Halkjaer SI, et al. Fecal microbiota transplantation in the treatment of chronic pouchitis: A systematic review. *Microorganisms*. 2020;8(9):1433.
19. Huttner BD, de Lastours V, Wassenberg M, et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: A randomized clinical trial. *Clin Microbiol Infect*. 2019;25(7):830-838.

20. Wang JW, Kuo CH, Kuo FC, et al. Fecal microbiota transplantation: Review and update. *J Formos Med Assoc.* 2019;118 Suppl 1:S23-S31.
21. Gupta K, Tappiti M, Nazir AM, et al. Fecal microbiota transplant in recurrent *Clostridium difficile* infections: A systematic review. *Cureus.* 2022;14(5):e24754.
22. Khanna, S., Assi, M., Lee, C. et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent *clostridioides difficile* infection. *Drugs* 82. 2022;1527–1538.
23. US Food and Drug Administration. FDA Approves First Fecal Microbiota Product. 2022